To investigate whether the EGFR-targeted 4-1BB-agonistic trimerbody can generate a similar effect, mice that rejected the implanted CT26hEGFR tumor by treatment with 3H3 IgG or 1D8N/CEGa1 (Fig. 5b) were rechallenged 50 days later with CT26mock cells. The gene discussed is EGFR; the disease is neoplasm.